0000718937 0000718937 2024-03-18 2024-03-18

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): March 18, 2024

STAAR Surgical Co mpany

(Exact Name of Registrant as Specified in Charter)

Delaware | 0-11634 | 95-3797439
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.)
25651 Atlantic Ocean Drive., Lake Forest, California |  | 92630
(Address of Principal Executive Offices) |  | (Zip Code)

Registrant’s Telephone Number, Including Area Code: 626-303-7902

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ | Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ | Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ | Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common | STAA | NASDAQ

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1 933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

Representatives of STAAR Surgical Company (the “Company”) will give presentations to investors commencing on March 18, 2024. A copy of the slide presentation they will share is furnished as Exhibit 99.1 to this Current Report and is incorporated herein by this reference.

Item 8.01 Other Events.

On March 18, 2024, the Company issued a press release reporting that more than three million of the Company's Implantable Collamer® Lenses (“ICLs”) have been sold globally, a copy of which is furnished as Exhibit 99.2 to this Current Report and is incorporated herein by this reference.

The information furnished herewith pursuant to Items 7.01 and 8.01 of this Current Report, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information in Items 7.01 and 8.01 of this Current Report, and Exhibits 99.1 and 99.2, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless of any general incorporation language in the filing.

Item 9.01 Financial Statements and Exhibits

Exhibit No. |  | Description
99.1 |  | Slide presentation of the Company dated March 18, 2024
99.2 |  | Press release of the Company dated March 18, 2024.
104 |  | Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

STAAR Surgical Company
March 18, 2024 | By: | /s/ Tom Frinzi
|  | Thomas Frinzi
|  | President and Chief Executive Officer